Bedside Snapshot

Use It For
Severe acute pain needing an opioid (trauma, fractures, burns, renal colic, abdominal pain); ischemic chest pain unrelieved by nitrates; sickle cell pain crisis; hospice pain and dyspnea
Adult Dose
  • Acute pain: 0.1 mg/kg IV/IO/IM slowly (max 10 mg initial); repeat after 10 min in 2.5–5 mg steps; reference ceiling 15 mg total
  • Hospice dyspnea: 1–5 mg IV, IM or subcut
  • PO: 10–20 mg solution or 15–30 mg tablet every 4 hr
Pediatric Dose
Off-label IV/IO/IM: 0.1 mg/kg slowly (max 10 mg); repeat after 10 min at half dose; field ceiling 15 mg total (reference ceiling, one EMS protocol). Oral, age 2+: 0.15–0.3 mg/kg (max 20 mg). Neonates: specialist only
Onset / Duration
IV: within minutes / 3–4 hr (peak 15–20 min; peak CNS depression up to 30 min); IM: 5–20 min / 3–4 hr (peak about 60 min); PO: peak about 60 min / 3–6 hr; neuraxial: up to 24 hr
Do Not Give / Hold If
Significant respiratory depression (RR <10, SpO₂ falling); unmonitored acute asthma; GI obstruction or ileus; MAOI within 14 days; circulatory shock (SBP <90 mmHg: hold)
Watch For
Oversedation then apnea, peaking up to 30 min after IV (sedation, RR, EtCO₂); hypotension (BP); flushing, itch, wheals at the injection site (histamine); myoclonus or seizures in kidney failure
Reversal / Rescue
Ventilate first. Naloxone 0.2–2 mg IV/IO/IM or 2–4 mg IN, repeat every 2–3 min; child 0.1 mg/kg IV/IO/IM (max 2 mg; IN max 4 mg). Differs from FDA label: label starts at 0.4 mg (adult), 0.01 mg/kg then 0.1 mg/kg (child).
Must Remember
Check concentration and route: injection runs from 1 mg/0.5 mL to 50 mg/mL (infusion-only vials, never push); Infumorph (10, 25 mg/mL) is neuraxial only; HYDROmorphone is not morphine

Indications

Emergency & Prehospital

  • Severe acute pain needing an opioid when non-opioid analgesia is inadequate (fractures, burns, trauma, renal colic, abdominal pain)
  • Ischemic chest pain not relieved by nitrates: second-line after nitroglycerin; use with caution in suspected acute coronary syndrome (ACS); some protocols prefer fentanyl
  • Hospice: pain and distressing dyspnea

ED / ICU / Transport

  • Multimodal analgesia with acetaminophen or ketorolac; sickle cell pain per institutional pathway
  • Postoperative IV, PCA or neuraxial morphine; patients arriving on a PCA or infusion

Other Uses

  • Cancer pain (oral, extended-release or subcut); long-term intrathecal or epidural infusion (Infumorph, specialist-managed)

Dosing & Administration

These doses are the national model EMS values (NASEMSO) and the FDA label. Local protocol may differ, so check it before you draw up anything.

Available Forms

  • IV: 4, 8 and 10 mg/mL vials; 2–15 mg/mL cartridges and syringes. IV or IM: 1 mg/0.5 mL, 2 and 4 mg/mL syringes (IM only with an IM-labeled product). Subcut and IO are off-label.
  • Infusion-only: 50 mg/mL, not for direct injection (pharmacy dilutes to 0.1–5 mg/mL)
  • Neuraxial: Duramorph 0.5 and 1 mg/mL; Infumorph 10 and 25 mg/mL, microinfusion devices only
  • Oral: 15 and 30 mg IR tablets; solution 2 and 4 mg/mL; 20 mg/mL for opioid-tolerant adults only; MS Contin 15–60 mg ER, not as needed
High-Alert Medication: Fatal errors start with a concentration mix-up. Mixing up 2 mg/mL with 10 or 15 mg/mL injection. A 50 mg/mL infusion vial that gets pushed. Infumorph given as an injection. A 20 mg/mL oral concentrate measured as 2 or 4 mg/mL. HYDROmorphone given at a morphine dose. Before every dose, check the drug, the concentration, the mg and mL, and the opioid tolerance.

Adult Dosing

IndicationDose & RouteRepeat / MaxNotes
Acute pain, weight-based (opioid-naive)
0.1 mg/kg IV, IO or IM; IV slowly
Max 10 mg initial; repeat after at least 10 min in 2.5–5 mg steps; field ceiling 15 mg total (reference ceiling, one EMS protocol)
High-alert Differs from NASEMSO (repeat after 5 min; IV peak 15–20 min). NASEMSO sets no cumulative maximum. Label 0.1–0.2 mg/kg IV every 4 hr. Start lower if older, frail or hypovolemic.
Incremental IV titration
2.5–5 mg IV slowly, every 10 min
Titrate to effect
High-alert Reassess before each repeat; CNS depression can lag up to 30 min.
Acute pain, IM
10 mg IM (70 kg adult)
Every 4 hr as needed
High-alert Avoid in shock or hypothermia: absorption is erratic, then doses absorb together.
Ischemic chest pain unrelieved by nitrates
2.5–5 mg IV slowly, every 10 min
Titrate to relief; field ceiling 15 mg total (reference ceiling, one EMS protocol); stop if hypotension
High-alert Nitrates first. In STEMI on ticagrelor, morphine left platelet inhibition weaker at 4 hr than fentanyl (PERSEUS). Some protocols prefer fentanyl.
Hospice / end-of-life dyspnea
1–5 mg IV, IM or subcut
Repeat as needed to comfort
High-alert Do not withhold for fear of respiratory depression when comfort is the goal. Subcut preferred when actively dying.
Pain, oral immediate-release
Solution 10–20 mg PO, or tablets 15–30 mg PO
Every 4 hr as needed
High-alert Use 2 or 4 mg/mL; never start 20 mg/mL in opioid-naive patients.
Persistent pain, extended-release (MS Contin)
15 mg PO every 8–12 hr if not opioid-tolerant
Over 60 mg single, or 120 mg/day total, only if opioid-tolerant
High-alert Swallow whole; crushing releases a potentially fatal dose. Not for acute pain.
Neuraxial (anesthesia only)
Duramorph epidural 5 mg (lumbar); intrathecal 0.2–1 mg single dose
Epidural max 10 mg/24 hr; no repeat intrathecal
High-alert Thoracic epidural raises respiratory depression, even at 1–2 mg. Observe at least 24 hr.

Pediatric Dosing

IndicationDose (per kg) & RouteMax Single / Max TotalNotes
Acute pain, IV/IO/IM (off-label)
0.1 mg/kg IV, IO or IM, slowly
Max initial 10 mg; repeat after 10 min at half dose; field ceiling 15 mg total (reference ceiling, one EMS protocol)
High-alert Direct-injection labels do not establish use under 18 yr. Differs from NASEMSO: repeat after 5 min. Push slowly; rapid push causes chest-wall rigidity. Differs from Nova Scotia EHS (more conservative): 2 mg/dose, 5 mg total. NASEMSO gives no reduced dose for young or frail children; 0.05 mg/kg is half the usual dose. Intranasal fentanyl is preferred without IV.
Oral solution, age 2–17 yr (FDA-labeled)
0.15–0.3 mg/kg PO every 4 hr as needed
Max initial dose 20 mg
High-alert Use only 2 or 4 mg/mL, never 20 mg/mL; round volumes under 1 mL to 0.1 mL.
Continuous IV infusion (FDA-labeled)
See Continuous Infusion
50 kg or more: start 1.5 mg/hr
High-alert PICU/NICU or specialist transport only; monitor cardiorespiratory function under 3 months.
Neonates and young infants, bolus
Specialist dosing only
—
Premature infants with chronic lung disease, up to 5–6 months, need close monitoring for depressed hypoxic drive.

Check the math with weight-based dosing or the Broselow tape.

Continuous Infusion

  • Adult, opioid-naive: 0.1–5 mg/mL in NS or D5W; start 0.02–0.1 mg/kg/hr and titrate to pain and sedation. Max 10 mg/hr if opioid-naive; opioid-tolerant patients may need 30 mg/hr or more. Sedation targets: analgosedation.
  • Pediatric, 1–16 yr: under 50 kg start 0.02–0.03 mg/kg/hr; 50 kg or more 1.5 mg/hr. Maintenance under 60 kg 0.01–0.06 mg/kg/hr; 60 kg or more 0.8–3 mg/hr.
  • Pediatric, under 1 yr: start 0.005–0.01 mg/kg/hr; specialist use; cardiorespiratory monitoring under 3 months.

Preparation & Administration

  • Dilution: an example EMS method is 10 mg in 9 mL NS, giving 1 mg/mL. Don't dilute prefilled syringes. Discard any that look darker than pale yellow or have precipitate. Infusions and PCAs run only on programmed pumps.
Dosing Notes:
  • Labels say 3–6 mg oral morphine may be needed to match 1 mg parenteral. Opioid-tolerant means at least 60 mg oral morphine/day, 25 mcg/hr transdermal fentanyl, 30 mg oral oxycodone or 8 mg oral hydromorphone daily (or equivalent) for 1 week or longer. Converting? Underestimate, then have rescue doses ready.

Contraindications & Precautions

Contraindications

  • Significant respiratory depression; unmonitored or severe asthma without resuscitative equipment
  • MAOI use or use within 14 days
  • Known or suspected GI obstruction or paralytic ileus; hypersensitivity to morphine
  • Neuraxial only: infection at the injection site, concomitant anticoagulants, uncontrolled bleeding diathesis

Precautions

  • Older, cachectic, COPD: apnea can happen at recommended doses. Start low.
  • Hypovolemia or shock: morphine releases histamine and dilates vessels, and the pressure can fall hard.
  • Head injury or raised ICP: retained CO₂ pushes ICP up, and opioids cloud the neurologic exam you need.
  • Kidney failure: active metabolites accumulate. Pick another opioid.
  • Seizures, biliary disease, pancreatitis: may worsen seizures or trigger sphincter of Oddi spasm. Sleep apnea: opioids cause central sleep apnea.
  • Long-term users: think about adrenal insufficiency and androgen deficiency.
  • Substance use history: addiction risk is higher. Severe pain still gets treated.
FDA Boxed Warning: The warning names four risks. Addiction, abuse and misuse. Life-threatening respiratory depression, worst at initiation and after dose increases. Profound sedation and death when it meets benzodiazepines or other CNS depressants. Neonatal opioid withdrawal syndrome. Oral products add concentration errors, fatal accidental ingestion by children and the opioid analgesic REMS. Extended-release products cause fatal overdose if crushed or chewed. Neuraxial use carries delayed respiratory depression, so observe for 24 hr.

Adverse Effects & Toxicity

Common

  • Sedation, dizziness, nausea and vomiting
  • Sweating, flushing, pruritus; wheals at the injection site (histamine)
  • Euphoria or dysphoria; constipation and urinary retention with repeated doses

Serious / Life-Threatening

EffectRecognitionManagement
Respiratory depression / apnea
Rising sedation, slow breathing, rising EtCO₂, falling SpO₂, pinpoint pupils; can peak up to 30 min after IV
Stimulate, airway maneuvers, BVM with O₂; naloxone titrated to breathing
Severe hypotension
Worse with hypovolemia, phenothiazines or anesthetics
Hold doses, supine position, fluids; vasopressor if refractory
Chest-wall rigidity
Stiff chest, hard to ventilate after rapid push
Stop the push; BVM with O₂; naloxone; if ventilation fails, neuromuscular blockade and intubation by credentialed providers
Neurotoxicity
Myoclonus, agitation, seizures with kidney failure or high IV doses; pain rising as dose rises (opioid-induced hyperalgesia)
Reduce dose or switch opioids; do not escalate; treat seizures
Serotonin syndrome
Agitation, hyperthermia, clonus with serotonergic drugs
Stop morphine and the serotonergic drug; supportive care
Anaphylaxis
Generalized urticaria, bronchospasm, hypotension (rare; local wheals are histamine)
Stop; epinephrine IM and anaphylaxis care

Overdose & Toxicity Management

  • Signs: respiratory depression, somnolence to coma, miosis (mydriasis with severe hypoxia); possible pulmonary edema, bradycardia, hypotension. Full pathway: opioid overdose.
  • First: protect the airway and ventilate; oxygen; vasopressors for shock. Cardiac arrest: CPR and ACLS/PALS take priority.
  • Antidote: naloxone. Adult: ventilate first, then 0.2–2 mg IV/IO/IM or 2–4 mg IN, repeat every 2–3 min, titrate to breathing. Differs from FDA label: label starts at 0.4 mg. Monitored iatrogenic or opioid-dependent over-sedation: 0.1–0.2 mg IV every 2–3 min to adequate breathing (label postoperative regimen). Child: 0.1 mg/kg IV/IO/IM (max 2 mg; IN max 4 mg per NASEMSO), repeat every 2–3 min. Differs from FDA label: label starts at 0.01 mg/kg, then 0.1 mg/kg. Postoperative depression in children (label): 0.005–0.01 mg IV increments, not per kg.
  • Re-sedation: naloxone wears off before morphine does, so keep monitoring until breathing is reliably maintained. Dependent patients? Titrate smaller doses to avoid withdrawal.
  • Late: toxic leukoencephalopathy shows up hours to weeks after recovery. Recovery on the call is not the end of the story.

Monitoring
  • Sedation: check it before each dose and again at peak: 15–20 min after IV (CNS up to 30 min), about 60 min after IM, subcut or PO. Use POSS or RASS. Hard to rouse? Hold, stimulate, assess breathing.
  • Breathing: continuous SpO₂ and EtCO₂ (capnography) during IV titration, PCA, transport and in high-risk patients. Act on RR <10/min, SpO₂ <90%, EtCO₂ >50 mmHg, a rise >10 mmHg, or a lost waveform. Ventilate. Naloxone.
  • BP and pain: get a baseline, then recheck after each IV dose. SBP <90 or MAP <65? Hold and give fluids. If pain climbs after dose increases, consider opioid-induced hyperalgesia.
  • ACS: serial 12-lead ECGs. If pain persists or the ECG changes, repeat the ECG and notify the receiving facility.
  • Neuraxial: watch sedation, RR and SpO₂ for at least 24 hr.
  • Labs: creatinine and eGFR before repeated dosing. Check glucose in diabetic or altered patients, since opioids can cause hypoglycemia. Treat low glucose. With kidney failure or new myoclonus, choose another opioid.
  • Bowel: with repeated or scheduled dosing, check stools, abdominal distension and bowel sounds daily. Once dosing goes past a single dose, start a bowel regimen per institutional protocol. If you suspect ileus or obstruction, hold.
  • Infusions: at every handoff, confirm the drug, concentration, rate, PCA lockout and last bolus.

Interactions & Compatibility

Clinically Significant Interactions

Drug / ClassEffectWhat To Do
Benzodiazepines and other CNS depressants (midazolam, alcohol, gabapentinoids, antipsychotics, muscle relaxants, general anesthetics, other opioids)
Hypotension, profound sedation, respiratory depression, coma, death (boxed warning)
Combine only when needed; lower both doses; continuous SpO₂ and EtCO₂
MAOIs (phenelzine, tranylcypromine, linezolid)
Serotonin syndrome or opioid toxicity
Contraindicated during or within 14 days; if an opioid is urgent, use small test doses of another opioid
Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, ondansetron, tramadol, methylene blue)
Serotonin syndrome
Observe during initiation and dose changes; stop morphine if suspected
Ticagrelor (oral P2Y12 inhibitor)
In STEMI, morphine left platelet inhibition weaker at 4 hr than fentanyl and delayed ticagrelor peak levels (PERSEUS, a small trial stopped early)
In STEMI, some protocols prefer fentanyl; follow local protocol
Mixed agonist-antagonists (buprenorphine, butorphanol, nalbuphine, pentazocine)
Reduced analgesia; precipitated withdrawal
Avoid in patients receiving a full agonist
P-gp inhibitors (quinidine, verapamil); cimetidine
P-gp inhibitors can double oral morphine exposure; cimetidine reported to cause apnea, confusion, twitching
Watch sedation and breathing; lower the morphine dose
Anticholinergics
Urinary retention, severe constipation, ileus
Monitor urine output and bowel function

IV Compatibility

  • Incompatible in admixture (label): soluble barbiturates, chlorothiazide, aminophylline, heparin, meperidine, methicillin, phenytoin, sodium bicarbonate, iodide, sulfadiazine, sulfisoxazole.
  • Prefilled syringes: give undiluted. Y-site: flush before and after other drugs; verify with an institutional resource.

Special Populations
  • Pediatrics: direct-injection labels don't establish use under 18 yr, so bolus dosing is off-label. Even one oral dose swallowed by a child can be fatal.
  • Neonates: specialist dosing only. Watch for neonatal opioid withdrawal syndrome. Support ventilation first. Naloxone can trigger abrupt withdrawal and seizures in a newborn exposed to chronic maternal opioids, so give it only per neonatal resuscitation guidance or medical direction.
  • Pregnancy: opioids cross the placenta. They can depress the newborn's breathing and prolong labor. Avoid them during or just before labor when other analgesia is appropriate. The label cites animal data showing malformations at high doses.
  • Lactation: morphine gets into breast milk. The label says breastfeeding is not recommended during MS Contin treatment. Otherwise, use the lowest dose and watch the infant for sedation.
  • Older adults: more sensitive to sedation and respiratory depression. Start low, then titrate slowly.
  • Renal impairment: M3G and M6G pile up, and that means prolonged sedation, myoclonus and seizures. In dialysis-dependent kidney failure, morphine is not recommended. Prefer fentanyl, or hydromorphone with a dose reduction. If it's unavoidable, use extreme caution at about one-quarter of the usual dose.
  • Hepatic impairment: cirrhosis drops clearance. Start lower.
  • Dosing weight and obesity: adult doses are capped (10 mg initial) instead of scaled to weight. Obesity and sleep apnea raise the risk of respiratory depression. Start low and watch EtCO₂. Cap pediatric mg/kg doses at the adult dose.
  • Opioid-tolerant patients: only they may receive the 20 mg/mL oral solution or high-dose extended-release products. Don't stop or rapidly cut long-term therapy. Fast tapering risks withdrawal, uncontrolled pain and suicide. Taper by no more than 10–25% of the total daily dose every 2–4 weeks (MS Contin label).
  • Discharge: teach caregivers about naloxone or nalmefene, especially when CNS depressants or children are in the home (label).

Field & Transport Considerations
  • Scope: Paramedics, critical-care transport and RNs work with it per protocol. The rules vary by state and agency.
  • Storage and control: 20–25 °C, protect from light, do not freeze. Schedule II: secure storage, counts and witnessed waste. Confirm 10 mg/mL vs 2 or 4 mg/mL at cross-check; label diluted syringes; state every dose in mg and mL.
  • Infusions and handoff: smart pump; verify concentration, rate, PCA dose, lockout and last bolus; continuous SpO₂ and EtCO₂; monitor 24 hr after neuraxial morphine. Hand off dose, route, total given, sedation, RR and EtCO₂ trend, BP and any naloxone.

Clinical Pearls
Do not chase the pain every 2 minutes: IV morphine takes 15–20 min to peak. The CNS can keep sinking for up to 30 min. Stack doses fast and they pile up on each other.
Hives along the vein are not anaphylaxis (NREMT, CEN): the itch and wheals are histamine, and they sit local to the vein. Ease off the push. Only generalized urticaria, bronchospasm or hypotension make it an allergy.
ACS: nitrates first: keep morphine for pain that won't quit after nitrates. In STEMI, ticagrelor's platelet inhibition ends up weaker at 4 hr with morphine than with fentanyl (PERSEUS).
Pulmonary edema is not a morphine indication (NREMT): for heart-failure pulmonary edema, the national model EMS guideline reaches for CPAP/BiPAP and nitroglycerin.

Pharmacology

Mechanism of Action

  • Full μ-opioid receptor agonist (relatively selective; binds other opioid receptors at higher doses). Analgesia has no ceiling, so sedation and respiratory depression are what limit the dose.
  • Brainstem respiratory centers respond less to CO₂. Hypoventilation and apnea follow, and so does miosis.
  • Histamine release and peripheral vasodilation bring flushing, pruritus, local wheals and orthostatic hypotension.
  • GI and urinary smooth muscle slows down and the sphincters clamp. Constipation, ileus and urinary retention follow.
  • Slow passage across the blood-brain barrier means the peak CNS effect trails the IV dose by up to 30 min.

Pharmacokinetics

RouteOnsetPeakDuration
IV
Within minutes
15–20 min (CNS depression up to 30 min)
3–4 hr
IM
5–20 min
About 60 min (label)
3–4 hr
Subcut
Variable
Similar to or slower than IM
3–6 hr
PO (immediate-release)
—
About 60 min
3–6 hr
Epidural / intrathecal
—
—
Up to 24 hr
  • Half-life: 1.5–2 hr in healthy adults (injection labels). Cirrhosis and kidney failure stretch it out.
  • Metabolism: glucuronidation turns morphine into M3G (about 50%) and M6G (about 5–15%). M6G is analgesic. M3G is not. Both pile up in kidney failure.

Names & Classification
Generic Name
Morphine sulfate (pentahydrate)
Brand Names
Duramorph, Infumorph (preservative-free injection); MS Contin (extended-release); generics
Pharmacologic Class
Natural opiate (phenanthrene alkaloid); full μ-opioid receptor agonist
Therapeutic Class
Opioid analgesic
Controlled Substance
C-II (DEA Schedule II)
ISMP High-Alert
Yes: ISMP high-alert medication (opioids, IV)
Look-Alike / Sound-Alike
HYDROmorphone / morphine; morphine 2 or 4 mg/mL oral solution / 20 mg/mL concentrate; Duramorph / Infumorph
Error-Prone Abbreviations to Avoid
"MS" and "MSO4" (read as magnesium sulfate); write "morphine" in full, with mg and mL

Related

References
  1. Fresenius Kabi USA (2026). Morphine sulfate injection, for intravenous or intramuscular use, CII: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f53de80-efc8-4930-b3e3-fba0d026af05
  2. Hikma Pharmaceuticals USA (2026). DURAMORPH (morphine sulfate injection), preservative-free, CII: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebb18761-e5c4-4238-bb84-f9549f500210
  3. Hikma Pharmaceuticals USA (2026). Morphine sulfate oral solution, CII: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca359246-4674-4b32-b8b2-673d32b7112f
  4. Hospira (2026). Morphine sulfate injection 50 mg/mL, for intravenous infusion after dilution, CII: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee8057d1-ed12-4e18-9efa-d83504abf612
  5. Rhodes Pharmaceuticals (2026). MS CONTIN (morphine sulfate) extended-release tablets, CII: Prescribing information (revised 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c354b3bf-86c0-4bb8-8b1f-be2164942698
  6. Hikma Pharmaceuticals USA (2025). INFUMORPH (morphine sulfate) preservative-free injection, for intrathecal or epidural continuous microinfusion, CII: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db9ac9e3-d761-4a99-9f34-4946ebe8f255
  7. Hospira (2026). Naloxone hydrochloride injection, USP: Prescribing information (revised 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8535cc84-ad4a-4d67-8480-fb5a2e3406f8
  8. National Association of State EMS Officials (NASEMSO) Medical Directors Council. (2022). National Model EMS Clinical Guidelines, Version 3.0: Pain management; Opioid poisoning/overdose; End-of-life care (copy hosted by Iowa HHS). https://hhs.iowa.gov/media/198/download
  9. 2025 AHA Guidelines for CPR and ECC, Part 10: Adult and Pediatric Special Circumstances of Resuscitation, Opioid Overdose and Table 4 (Commonly Used Doses of Antidotes). (2025). Circulation. https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/adult-and-pediatric-special-circumstances-of-resuscitation/content/guidelines-accordion/toxicology-nested-section/table-4
  10. Nova Scotia Emergency Health Services. (2025). Medication: Morphine (EHS medication protocol, PDN 6957.08, updated August 21, 2025). https://novascotia.ca/dhw/ehs/documents/medications/EHS-Morphine.pdf
  11. Tobin, D. G., Lockwood, M. B., Kimmel, P. L., Dember, L. M., Eneanya, N. D., Jhamb, M., et al. (2022). Opioids for chronic pain management in patients with dialysis-dependent kidney failure. Nature Reviews Nephrology, 18(2), 113–128. https://pmc.ncbi.nlm.nih.gov/articles/PMC8792317/
  12. Iglesias, J. F., Valgimigli, M., Carbone, F., et al. (2022). Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: full results of the PERSEUS randomized trial. Cardiology Journal, 29(4), 591–600. https://pubmed.ncbi.nlm.nih.gov/35762079/

Last updated Spotted something wrong? Report an error and include the page URL.

Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.